symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CWBR,2.47,1.830971,19842,7180117,0,1.43-6.9,-0.11,"CohBar, Inc.",USD,0001522602,US19249J1097,19249J109,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.cohbar.com,"CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.","Dr. Joseph J. Sarret J.D., M.D.",Healthcare,US,9,650 446 7888,1455 Adams Drive,Menlo Park,CA,94025,0.367732,1.82227,https://financialmodelingprep.com/image-stock/CWBR.png,2017-12-15,False,False,True,False,False
